Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...
Medicaid expansion under the Affordable Care Act (ACA) significantly increased the number of people at risk of HIV diagnosis ...
Rutgers Health researchers found that prescription rates for preexposure prophylaxis rose overall, but racial disparities ...
Zacks Investment Research on MSN
GILD's Investigational Regimen for HIV Treatment Meets Primary Goal
Gilead Sciences, Inc. GILD announced that its investigational single-tablet regimen (STR) of bictegravir and lenacapavir for ...
The Sindh Healthcare Commission (SHCC) has taken immediate action following the emergence of HIV cases at Kulsoom Bai Valika Hospital in Karachi's Keamari district. Director Anti-Quackery Dr Zubair ...
The agency approved Gilead Sciences' pill, Truvada, as a preventive measure for people who are at high risk of acquiring HIV through sexual activity, such as those who have HIV-infected partners.
The agency approved Gilead Sciences' Stribild as a once-a-day treatment to control HIV in adults who have not previously been treated. The pill contains two previously approved antiviral drugs, ...
This article is brought to you by our exclusive subscriber partnership with our sister title USA Today, and has been written by our American colleagues. It does not necessarily reflect the view of The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback